OCEA Stock Forecast 2025-2026
Distance to OCEA Price Targets
OCEA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ocean Biomedical (OCEA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OCEA and similar high-potential opportunities.
Latest OCEA Stock Price Targets & Analyst Predictions
OCEA has shown a year-to-date change of -98.2% and a 1-year change of -99.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for OCEA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCEA Analyst Ratings
OCEA Price Target Range
Latest OCEA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCEA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 31, 2023 | Taglich Brothers | Howard Halpern | Speculative Buy | Initiates | $20.00 |
| May 25, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $17.00 |
| Apr 27, 2023 | EF Hutton | Michael King | Buy | Maintains | $17.00 |
| Apr 13, 2023 | EF Hutton | Michael King | Buy | Reiterates | $10.00 |
| Mar 16, 2023 | Fundamental Research Corp. | Sid Rajeev | Buy | Initiates | $16.40 |
| Mar 13, 2023 | EF Hutton | Michael King | Buy | Initiates | $10.00 |
Ocean Biomedical Inc. (OCEA) Competitors
The following stocks are similar to Ocean Biomedical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ocean Biomedical Inc. (OCEA) Financial Data
Ocean Biomedical Inc. has a market capitalization of $6.30M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +9.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ocean Biomedical Inc. (OCEA) Business Model
About Ocean Biomedical Inc.
Develops innovative therapeutics for unmet medical needs.
Ocean Biomedical Inc. collaborates with research universities and medical institutions to develop clinical applications from groundbreaking discoveries. The company generates revenue by commercializing these innovative therapeutics across various sectors, including oncology and infectious diseases.
By bridging the gap between research and treatment, Ocean Biomedical aims to transform scientific breakthroughs into viable medical solutions, enhancing patient care and health outcomes. The company's involvement in the dynamic healthcare market positions it as a significant player in addressing complex diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. M. Michelle Berrey M.D., M.P.H.
Country
United States
IPO Year
2021
Website
www.oceanbiomedical.comOcean Biomedical Inc. (OCEA) Latest News & Analysis
Latest News
Ocean Biomedical (NASDAQ: OCEA) has published research showing its cancer immunotherapy candidates synergize with tyrosine kinase inhibitors used for non-small cell lung cancer, potentially enhancing treatment efficacy.
Ocean Biomedical's entry into the bispecific antibody market and positive research findings on its immunotherapy candidates could enhance its competitive edge and market valuation, attracting investor interest.
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
2 months agoOcean Biomedical (NASDAQ: OCEA) has secured additional NIH funding for malaria vaccine research led by Dr. Jonathan Kurtis. New FDA guidance may expedite development of their lipid-encapsulated vaccine.
Ocean Biomedical's NIH funding and FDA support for its malaria vaccine enhance its growth potential, signaling a promising future and possible increased investor interest.
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
5 months agoOcean Biomedical, Inc. (NASDAQ: OCEA) received a notice from Nasdaq for failing to file its Q3 2024 report, violating Listing Rule 5250(c)(1), which mandates timely SEC filings.
Ocean Biomedical's non-compliance with Nasdaq reporting rules may lead to delisting, raising concerns about its financial health and potentially impacting stock value.
Ocean Biomedical, Inc. (NASDAQ: OCEA) received a Nasdaq Staff Determination Letter for failing to meet filing requirements for its Form 10-K and Forms 10-Q. The company plans to appeal.
Ocean Biomedical's failure to file required reports raises concerns about its financial health and compliance, potentially affecting stock price and investor confidence.
A license for YKL-40 inhibitors, including lead molecule OAT-3912, has been secured, showing potential in cancer and inflammatory diseases. It also includes a patent for a molecular screening test.
The licensing of YKL-40 inhibitors, particularly OAT-3912, signals potential breakthroughs in treating cancer and inflammatory diseases, which may enhance the company's market position and attract investment.
Ocean Biomedical's anti-CHI3L1 patent covers methods for targeting various cancers, including lung, glioblastoma, prostate, melanoma, and breast cancer.
Ocean Biomedical's patent on Anti-CHI3L1 for multiple cancers expands its market potential, signaling possible revenue growth and attracting investor interest in the biotech sector.
Frequently Asked Questions About OCEA Stock
What is Ocean Biomedical Inc.'s (OCEA) stock forecast for 2025?
Analyst forecasts for Ocean Biomedical Inc. (OCEA) are not currently available. The stock is trading at $0.01.
Is OCEA stock a good investment in 2025?
Analyst ratings for OCEA are not currently available. The stock is currently trading at $0.01. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCEA stock?
Price predictions from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is Ocean Biomedical Inc.'s business model?
Ocean Biomedical Inc. collaborates with research universities and medical institutions to develop clinical applications from groundbreaking discoveries. The company generates revenue by commercializing these innovative therapeutics across various sectors, including oncology and infectious diseases.
What is the highest forecasted price for OCEA Ocean Biomedical Inc.?
Price targets from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is the lowest forecasted price for OCEA Ocean Biomedical Inc.?
Price targets from Wall Street analysts for OCEA are not currently available. The stock is trading at $0.01.
What is the overall OCEA consensus from analysts for Ocean Biomedical Inc.?
Analyst ratings for OCEA are not currently available. The stock is trading at $0.01.
How accurate are OCEA stock price projections?
Stock price projections, including those for Ocean Biomedical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.